Covered recipient · General Payments record
MARIA RODRIGUEZ
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$1,406.58
- Reported across 43 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $951.71 | 29 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $372.05 | 10 |
| Novo Nordisk AS | $259.03 | 11 |
| Acerta Pharma LLC | $134.29 | 2 |
| GlaxoSmithKline, LLC. | $106.31 | 2 |
| DEXCOM, INC. | $23.11 | 1 |
| Phadia US Inc. | $21.18 | 1 |
| Amgen Inc. | $18.83 | 1 |
| Currax Pharmaceuticals LLC | $16.91 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (29)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | $18.83 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111690762 | CMS |
| AstraZeneca Pharmaceuticals LP | $125.00 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104287460 | CMS |
| AstraZeneca Pharmaceuticals LP | $9.29 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104279365 | CMS |
| Currax Pharmaceuticals LLC | $16.91 | 12/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089513082 | CMS |
| Dexcom, Inc. | $23.11 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153319192 | CMS |
| GlaxoSmithKline, LLC. | $92.22 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116648463 | CMS |
| GlaxoSmithKline, LLC. | $14.09 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116425857 | CMS |
| Lilly USA, LLC | $14.68 | 01/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135165807 | CMS |
| Lilly USA, LLC | $14.71 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135150142 | CMS |
| Lilly USA, LLC | $117.93 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135165483 | CMS |
| Lilly USA, LLC | $21.02 | 03/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135147000 | CMS |
| Lilly USA, LLC | $105.52 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135109392 | CMS |
| Lilly USA, LLC | $16.23 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135165809 | CMS |
| Lilly USA, LLC | $21.89 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135153488 | CMS |
| Lilly USA, LLC | $21.53 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135159620 | CMS |
| Lilly USA, LLC | $22.09 | 06/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135153490 | CMS |
| Lilly USA, LLC | $16.45 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135153492 | CMS |
| Novo Nordisk Inc | $12.67 | 01/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097169231 | CMS |
| Novo Nordisk Inc | $16.11 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097403930 | CMS |
| Novo Nordisk Inc | $21.60 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097307385 | CMS |
| Novo Nordisk Inc | $1.87 | 03/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097585089 | CMS |
| Novo Nordisk Inc | $16.77 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096815784 | CMS |
| Novo Nordisk Inc | $14.03 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096871606 | CMS |
| Novo Nordisk Inc | $13.45 | 08/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096679853 | CMS |
| Novo Nordisk Inc | $23.36 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096929982 | CMS |
| Novo Nordisk Inc | $110.91 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097539715 | CMS |
| Novo Nordisk Inc | $13.61 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097296738 | CMS |
| Novo Nordisk Inc | $14.65 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096613756 | CMS |
| Phadia US Inc. | $21.18 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1067582884 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.